Allergan Bolsters Botox Biz With Medy-Tox Deal
This article was originally published in The Pink Sheet Daily
The specialty pharma is highly protective of its slot as the market leader in neuro modulators and has been working to add indications, as well as conduct deals that can help it retain its position with its Botox franchise.
You may also be interested in...
Allergan partnered with MAP in 2011 for rights to commercialize Levadex for acute migraine in North America, but now will control 100% of the product’s revenue, creating a complementary product to Botox in chronic migraine. Levadex has an April 15 PDUFA date at FDA.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.